
**What is Claimed:**

1. A pharmaceutical formulation comprising a KZR-616 maleate salt, and a sugar, wherein KZR-616 has a structure , the sugar comprises trehalose, and the formulation is a lyophilized formulation.

2. The formulation of claim 1, having a pH of 3.0 to 4.5, as measured prior to lyophilization.

3. The formulation of claim 2, having a pH of 4.2.

4. The formulation of any one of claims 1 to 3, further comprising a succinate buffer.

5. The formulation of any one of claims 1 to 4, wherein the KZR-616 is present in an amount of 100 mg/mL to 200 mg/mL based upon the weight of the KZR-616 free base.

6. The formulation of any one of claims 1 to 5, wherein the sugar is present at an amount of 1.5wt% to 3 wt%, based upon total weight of the formulation.

7. The formulation of any one of claims 1 to 6, wherein the sugar further comprises mannitol.

8. The formulation of any one of claims 1 to 7, wherein the lyophilized formulation has a moisture content of less than 1%.

9. The formulation of any one of claims 4 to 8, having a pH of 4.1 to 4.3 (as measured when reconstituted) after storage at 5°C, 25°C, or 40°C for at least six months.

10. The formulation of any one of claims 1 to 9, having a reconstitution time of less than 4.5 minutes after storage at 5°C, 25°C, or 40°C for at least six months.

11. The formulation of any one of claims 1 to 10, wherein the lyophilized formulation has a moisture content of less than 1% after storage at 5°C, 25°C, or 40°C for at least six months.

12. The formulation of any one of claims 1 to 11, wherein the KZR-616 is at least 93% pure after storage at 5°C, 25°C, or 40°C for at least six months.

13. A reconstituted formulation comprising the formulation of any one of claims 1 to 12 and a solvent for reconstitution.

14. The reconstituted formulation of claim 13, wherein the solvent for reconstitution comprises water for injection (WFI) or aqueous 5% dextrose.

15. The reconstituted formulation of claim 13 or 14 having an osmolality of 275 to 325 mOsm.

16. The reconstituted formulation of any one of claims 13 to 15 for use in the treatment of lupus nephritis or systemic lupus erythematosus (SLE).

17. The reconstituted formulation of any one of claims 13 to 15 for use in the treatment of inflammation.